Bristol Myers Squibb (BMY) Depreciation and Depletion (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Depreciation and Depletion data on file, last reported at $139.0 million in Q1 2026.

• Quarterly Depreciation and Depletion fell 15.76% year-over-year to $139.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $595.0 million (down 9.98% YoY) and the FY2025 annual result came in at $621.0 million, down 4.61% from the prior year.
• Depreciation and Depletion advanced to $139.0 million in Q1 2026 per BMY's latest filing, from $132.0 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $169.0 million in Q4 2024 and bottomed at $132.0 million in Q4 2025.
• The 5-year median for Depreciation and Depletion is $153.0 million (2022), against an average of $153.5 million.
• The widest annual swing landed in 2022, when Depreciation and Depletion rose 11.68%; it then dropped 21.89% in 2025.
• Tracing BMY's Depreciation and Depletion over 5 years: stood at $153.0 million in 2022, then climbed by 6.54% to $163.0 million in 2023, then increased by 3.68% to $169.0 million in 2024, then retreated by 21.89% to $132.0 million in 2025, then increased by 5.3% to $139.0 million in 2026.
• Per Business Quant, the three latest BMY Depreciation and Depletion figures stand at $139.0 million (Q1 2026), $132.0 million (Q4 2025), and $159.0 million (Q3 2025).

Peer Comparison